Related Experiment Video
Updated: Jun 14, 2026
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Rituximab in high-grade lymphoma.
Carsten Zwick1, Niels Murawski, Michael Pfreundschuh
1Innere Medizin I, Saarland University Medical School, Homburg, Germany.
Seminars in Hematology
|March 31, 2010
Summary
The anti-CD20 antibody rituximab significantly improved outcomes for lymphoma patients when added to chemotherapy. However, new treatments are needed for patients who relapse after rituximab therapy.
Area of Science:
- Hematology
- Oncology
- Immunotherapy
Background:
- The standard treatment for aggressive B-cell lymphoma was cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) for over 25 years.
- The introduction of rituximab in 1997 marked a significant advancement in lymphoma treatment.
Purpose of the Study:
- To review the impact of rituximab on lymphoma treatment.
- To identify challenges and future directions in rituximab-based immunochemotherapy.
Main Methods:
- Review of randomized trials and clinical data.
- Analysis of treatment outcomes in follicular and diffuse large B-cell lymphoma (DLBCL).
Main Results:
- Rituximab addition to CHOP chemotherapy significantly improved response rates and survival in DLBCL.
- Despite improvements, challenges remain in optimizing chemotherapy partners and rituximab dosage/schedule.
Conclusions:
- Rituximab has revolutionized lymphoma treatment, but further research is needed for optimal use.
- New second-line therapies are urgently required for patients relapsing after rituximab-containing regimens.
